The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
 
Cathy Eng
Honoraria - Roche; Sanofi
Consulting or Advisory Role - Bayer Schering Pharma; Roche/Genentech; Sanofi
Research Funding - ArQule; Keryx
Travel, Accommodations, Expenses - Genentech/Roche; Sanofi
 
Eric Van Cutsem
Research Funding - Amgen (Inst)
 
Elzbieta Nowara
No Relationships to Disclose
 
Anna Swieboda-Sadlej
No Relationships to Disclose
 
Niall C. Tebbutt
Research Funding - Amgen (Inst)
 
Edith P. Mitchell
Honoraria - Sanofi
Consulting or Advisory Role - Genentech
Research Funding - Genentech (Inst); sanofi (Inst)
 
Irina Davidenko
No Relationships to Disclose
 
Oliver Lee
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Kelly Smith Oliner
Employment - Amgen; Amgen (I)
Stock and Other Ownership Interests - Amgen; Amgen (I)
 
Marco Schupp
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Elwyn Loh
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Roger Sidhu
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Taiho Pharmaceutical